Evidence map›Paper›PMID 28265829›Full record

ArticleDigestive diseases and sciences2017

A Multicenter Study of a Fluorescence In Situ Hybridization Probe Set for Diagnosing High-Grade Dysplasia and Adenocarcinoma in Barrett's Esophagus.

John M Poneros, Adam S Faye, Emily G Barr Fritcher, Ananda Sen, Sharmila Anandasabapathy, Robert S Bresalier, Norman Marcon, D Kim Turgeon, Henry Appelman, Daniel Normolle and 3 more

Abstract readMulticenter StudyValidation Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Digestive diseases and sciences, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Diagnostic and Prognostic Biomarkers for Barrett's Esophagus.Gastroenterology clinics of North America · 2026
    Review
  3. Article
  4. Review
  5. Utility of ancillary studies in the diagnosis and risk assessment of Barrett's esophagus and dysplasia.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2022
    Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 9 institutions in 2 countries.

John M PonerosDepartment of Gastroenterology, Columbia University Medical Center, 161 Fort Washington Avenue, Suite 862, New York, NY, 10032, USA. jmp14@cumc.columbia.edu.
Adam S FayeDepartment of Internal Medicine, Columbia University Medical Center, 177 Fort Washington Avenue, Milstein 6C-12, New York, NY, 10032, USA.
Emily G Barr FritcherDepartment of Laboratory Medicine and Pathology, Mayo Clinic, 200 First SW, Rochester, MN, 55905, USA.
Ananda SenDepartment of Biostatistics, University of Michigan Medical Center, Ann Arbor, MI, USA.
Sharmila AnandasabapathyDepartment of Gastroenterology, Baylor College of Medicine, Baylor St. Luke's Medical Center Clinic, 7200 Cambridge Street Suite 10C, Houston, TX, 77030, USA.
Robert S BresalierDepartment of Gastroenterology, University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Unit 1466, Houston, TX, 77030, USA.
Norman MarconDepartment of Gastroenterology, University of Toronto, Toronto, ON, Canada.
D Kim TurgeonDepartment of Internal Medicine, University of Michigan Medical Center, Ann Arbor, MI, USA.
Henry AppelmanDepartment of Pathology, University of Michigan Medical Center, 1301 Catherine St., Ann Arbor, MI, 48109, USA.
Daniel NormolleDepartment of Biostatistics, University of Pittsburgh Cancer Institute, 201 North Craig Street, Sterling Plaza Suite 325, Pittsburgh, PA, 15213, USA.
Larry E MorrisonAbbott Molecular, Inc., Des Plaines, IL, USA.
Dean E BrennerDepartment of Internal Medicine, University of Michigan Medical Center, Ann Arbor, MI, USA.
Kevin C HallingDepartment of Laboratory Medicine and Pathology, Mayo Clinic, 200 First SW, Rochester, MN, 55905, USA.
University of Michigan–Ann Arbor · USColumbia University Irving Medical Center · USMayo Clinic · USA. Alfred Taubman Health Care Center · USAbbott (United States) · USBaylor College of Medicine · USThe University of Texas MD Anderson Cancer Center · USUniversity of Toronto · CAUPMC Hillman Cancer Center · US

Funding

VECTOR CORE FACILITYP30CA047904 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Jessie Nedrow · 1988 to 2026
$158.0M
Great Lakes/New England Clinical Validation CenterU01CA086400 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI RICCIARDIELLO, LUIGI, SYNGAL, SAPNA · 2000 to 2025
$26.0M
NCI NIH HHS P30 CA047904NCI NIH HHS U01 CA086400
6 · The paper itself

Abstract

BACKGROUND AND

aimsPreliminary single-institution data suggest that fluorescence in situ hybridization (FISH) may be useful for detecting high-grade dysplasia (HGD) and esophageal adenocarcinoma (EA) in patients with Barrett's esophagus (BE). This multicenter study aims to validate the measurement of polysomy (gain of at least two loci) by FISH as a way to discriminate degrees of dysplasia in BE specimens.

methodsTissue specimens were collected from four different hospitals and read by both the local pathology department ("Site diagnosis") and a single central pathologist ("Review diagnosis") at a separate institution. The specimens then underwent FISH analysis using probes 8q24 (MYC), 9p21 (CDKN2A), 17q12 (ERBB2), and 20q13 (ZNF217) for comparison. A total of 46 non-BE, 42 non-dysplastic specialized intestinal metaplasia (SIM), 23 indefinite-grade dysplasia (IGD), 10 low-grade dysplasia (LGD), 29 HGD, and 42 EA specimens were analyzed.

resultsWe found that polysomy, as detected by FISH, was the predominant chromosomal abnormality present as dysplasia increased. Polysomy was also the best predictor for the presence of dysplasia or EA when comparing its area under the curve to that of other FISH abnormalities. We observed that if at least 10% of cells had polysomy within a specimen, the FISH probe was able to differentiate between EA/HGD and the remaining pathologies with a sensitivity of 80% and a specificity of 88%.

conclusionsThis study demonstrates that using FISH to determine the percentage of cells with polysomy can accurately and objectively aid in the diagnosis of HGD/EA in BE specimens.

Indexed as

AdenocarcinomaBarrett EsophagusEsophageal NeoplasmsHumansIn Situ Hybridization, FluorescenceROC CurveSensitivity and SpecificityBarrett’s esophagusDysplasiaEndoscopyFISHHistopathologyPolysomy

Identifiers

PMID28265829
PMCPMC6052443
OpenAlexW2592696493

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.